Key insights
- Halozyme (HALO) is a biotech firm licensing drug delivery tech. Its stock dropped 23% due to GLP-1 competition impacting partner drugs and patent cliffs. Despite these headwinds, the company boasts 85% recurring revenue and a strong royalty model. The author believes Wall Street is overreacting, presenting a buying opportunity with a 20% margin of safety based on intrinsic value.
TL;DR: Halozyme ($HALO) licenses drug delivery tech that transforms hour-long IV infusions into 5-minute subcutaneous injections. 62% royalty revenue, 10 launched products with 20+ more in development, $781M owner earnings. The stock dropped 23% because GLP-1 competition is hurting some partner drugs. I think Wall Street is overreacting to a temporary headwind on a business with locked-in royalty growth. Trading at $67 vs. intrinsic value of $84 (20% margin of safety).
The Business
HALO's ENHANZE platform is licensed to pharma giants including Roche, Johnson & Johnson, Pfizer, and Takeda. The technology uses an enzyme that temporarily opens tissue under the skin, allowing large drug volumes to be injected subcutaneously instead of IV. For patients, this means 5-minute injections instead of hour-long infusions.
What makes them sticky is the royalty model. Once a partner launches a drug using ENHANZE, Halozyme collects royalties for the life of the patent with almost no additional cost. 10 products are already launched and generating royalties. 20+ more are in development.
The Numbers
| | | |---|---| | Operating Cash Flow | $677.42M | | Stock-Based Compensation | -$57.53M | | Smoothed CapEx (5yr avg) | -$13.62M | | WC Adjustment | +$174.59M | | Owner Earnings | $780.86M | | Diluted Shares | 117.78M | | OE Per Share | $6.63 |
CapEx is minimal (0.90% of revenue) because this is a licensing business. No factories, no warehouses.
Quality metrics:
- Revenue Growth: +37.55% YoY - Revenue Mix: 62% royalties, 25% device/API, 13% milestones - Recurring Revenue: ~85% - Net Debt: $1.83B (liquid assets: $319M) - Buybacks TTM: $320M
Why It's Cheap
The stock dropped 23% from its highs. Two things spooked Wall Street:
- GLP-1 competition (Ozempic/Wegovy) is cannibalizing some partner drugs, particularly in the diabetes space. 2. Patent cliffs on major royalty contributors like Herceptin SC and Darzalex SC create uncertainty about future revenue.
Why I Think The Market Is Wrong
The royalty pipeline is deep. 20+ drugs in development means new launches will offset patent expirations. The business model is capital-light with almost no incremental cost to collect royalties. Management is buying back $320M in stock, signaling they think shares are undervalued. At 10x owner earnings, you're paying a reasonable multiple for a business with 85% recurring revenue.
Disclosure: I hold a position in HALO. Hard data from filings, AI-assisted writing, personal review and position. This is not financial advice.